What is aggressive invasive cancer of the esophagus?

What is Aggressive Invasive Cancer of the Oesophagus

Aggressive invasive oesophageal cancer refers to locally advanced tumours (≥T2 or N1, M0 stage) that invade beyond the superficial layers into deeper structures or involve regional lymph nodes, requiring multimodality treatment for any chance of cure 1.

Key Defining Features

Aggressive invasive oesophageal cancer encompasses tumours with the following characteristics:

• T3/T4 tumours: Invasion through the muscularis propria into adventitia (T3) or invasion of adjacent structures like pleura, pericardium, diaphragm, or peritoneum (T4a), or invasion of unresectable structures like aorta, vertebral body, or trachea (T4b) 2
• Node-positive disease (N1-N3): Regional lymph node involvement, which dramatically worsens prognosis
• No distant metastases (M0): Still potentially curable with aggressive multimodality therapy

Two Distinct Histologic Entities

The term encompasses two fundamentally different diseases that must be distinguished 3:

Squamous Cell Carcinoma (SCC)

• More common in East Asian and Middle Eastern populations
• Often accompanied by head and neck second primary tumours (6.7% prevalence) 2
• Requires head and neck examination to exclude synchronous primaries
• Can be treated with definitive chemoradiotherapy without surgery as an equivalent option 1

Adenocarcinoma (AC)

• More prevalent in Western countries with increasing incidence
• Often arises at the oesophagogastric junction (OGJ)
• When involving the anatomical cardia, 15% have occult peritoneal metastases requiring laparoscopy for staging 2
• Requires either preoperative chemoradiotherapy or perioperative chemotherapy 1

Clinical Presentation and Impact

These aggressive tumours cause severe morbidity:

• >50% of patients lose >5% body weight before treatment
• 40% lose >10% body weight, which independently increases operative risk and worsens survival regardless of BMI 2
• Dysphagia is common, sometimes preventing passage of endoscopic ultrasound equipment
• Reduced physical activity and fitness predict worse long-term survival 2

Staging Requirements for Aggressive Disease

Accurate staging is critical and must include 2:

• Endoscopy with biopsy
• Contrast-enhanced CT or FDG-PET/CT (PET-CT identifies otherwise undetected distant metastases in 10-15% of cases, preventing futile surgery)
• Endoscopic ultrasound (EUS) for T and N staging, particularly useful for:
  • Assessing T4b status with invasion of airways, pericardium, or aorta
  • Identifying lymph nodes outside radiation fields or resection limits
  • Note: EUS has low accuracy for T1 tumours and may be impossible with tumour stricture
• Bronchoscopy with endobronchial ultrasound when tumour approaches central airways
• Laparoscopy for T3/T4 adenocarcinomas at the OGJ to rule out peritoneal metastases

Treatment Paradigm

Multimodality therapy is mandatory for locally advanced disease 1. Surgery alone yields poor outcomes, particularly in SCC.

For Adenocarcinoma:

• Preoperative chemoradiotherapy (trimodality), OR
• Perioperative chemotherapy (pre- and post-operative)

For Squamous Cell Carcinoma:

• Preoperative chemoradiotherapy followed by surgery, OR
• Definitive chemoradiotherapy without surgery (equivalent option)

Rare Aggressive Variants

Several exceptionally aggressive subtypes exist:

• Neuroendocrine carcinoma (NEC): Poorly differentiated with unfavorable prognosis, requires platinum-etoposide-based regimens 4
• Large-cell neuroendocrine carcinoma (LCNEC): Can exhibit pagetoid spread extending many centimeters beyond visible tumour 5
• Adenosquamous carcinoma: Rare hybrid tumour with features of both histologies, extremely aggressive 6
• Small cell carcinoma: Exceptionally rare and aggressive, similar to pulmonary small cell carcinoma 7

Critical Pitfalls

• Do not rely on surface biopsies alone for submucosal tumour-like lesions—these can represent intramural invasion of SCC mimicking benign disease; EUS-guided fine needle aspiration is essential 8
• Do not skip PET-CT in surgical candidates—it prevents futile operations by detecting occult metastases
• Do not skip laparoscopy in T3/T4 OGJ adenocarcinomas—15% have peritoneal disease 2
• Do not neglect nutritional support—weight loss >10% independently worsens operative risk and survival 2